Brief: UBS Group's Short Position In Shanghai Henlius Biotech Reduced To 0% On Dec 2 From 2.07% - HKEX
05/12/2024 09:18
Dec 5 (Reuters) - HKEX:
* UBS GROUP'S SHORT POSITION IN SHANGHAI HENLIUS BIOTECH
2696.HK
REDUCED TO 0% ON DEC 2 FROM 2.07% - HKEX
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln